The stock's average target of $32.33 is 286.26% above today's ($8.37) share price. Citigroup's PT indicates a potential downside of -1.18%. One research analyst has rated the stock with a sell rating, ten have given a …
GlaxoSmithKline plc
Wall: And what's the second stock? Gergel: The second stock is GlaxoSmithKline (GSK). Clearly, very well-known as pharmaceutical stock. It's being transformed by deal with Novartis in 2015, which has made them …
Stock Picks
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up …
ZACKS2mon
GlaxoSmithKline
Investors in GlaxoSmithKline plc (NYSE: GSK) saw new options become available today, for the January 2017 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the GSK options chain …
Forbes4mon
GlaxoSmithKline
Merger mania is sweeping the stock market. It seems no company is safe as both ... or a number of buyers may swoop down on GlaxoSmithKline (LSE: GSK) to break up the business and get their hands on the firm’s …
Glaxo
GlaxoSmithKline Plc (ADR) (NYSE:GSK) stock has performed moderately well so far this year, marked with some steep increases and declines as well. After a long period of consistent declines experienced last year, …
GlaxoSmithKline plc (ADR) (GSK) stock was up on Monday following results from a clinical study. GSK reported that its late-stage study of a triple combination therapy designed to treat patients with chronic …
GlaxoSmithKline plc (LON:GSK) insider Moncef Slaoui purchased 58 shares of GlaxoSmithKline plc stock in a transaction that occurred on Monday, January 9th. The shares were acquired at an average price of GBX …
Thecer2mon
GlaxoSmithKline
LONDON -- Successful investors use a disciplined approach to picking stocks, and checklists can be a great way to make sure you've covered all the bases. 1. Prospects The pharmaceutical industry is riding a demographic …